Novavax’s partnership with Sanofi allows the pharma giant to explore potential combinations of assets from both companies, and it’s a blueprint for the kinds of alliances the vaccine developer is pursuing. Rather than commercializing vaccines, Novavax aims to turn its research into business development deals, R&D executive Ruxandra Draghia-Akli said.
BIO’s new president and CEO is a familiar face. John Crowley, a longtime BIO board member, was named the life sciences industry trade group’s new leader, starting in March.
Your varicose or spider veins may indicate an underlying problem, so finding the right vein specialist is crucial. Discover the best vein clinics in Orlando.
Drug prices are on the minds of patients and politicians. The November election is expected to tip the balance of power in Congress and a panel held during the Biotechnology Innovation Organization’s annual meeting discussed what that change could mean for drug price legislation.
Biopharmaceutical companies and public health officials have learned a great deal about pandemic response in the last two years. A panel discussion during the annual meeting of the Biotechnology Innovation Organization explored some of the lessons from Covid-19 and how they can prepare us for the next pandemic.
In an open letter published by BIO, the executives emphasized the importance of science-driven evaluation of medicines and regulatory independence. The letter came amid growing concern about political pressure over the FDA, as well as lack of diversity in trials and companies being too quick to announce data that are inconclusive.
BIO's first annual report on diversity in the workplace found room for improvement, as biotech workforces - especially at the executive level - were found to not represent the U.S. population. The report was based on a survey of nearly 100 companies in late spring 2019.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
More than 150 people - including biotechnology and investment executives and academics - have signed a letter warning that actions dismissals of Chinese scientists create a hostile climate that threatens U.S. leadership in biomedical science.
While the U.K. biopharma industry will likely continue to play a significant role on the global stage, it could have trouble attracting talent, while European firms prepare for a worst-case scenario.
The industry should also not be shy about going after actors who increase prices on drugs without increasing value, said the chair, Jeremy Levin, who is CEO of Ovid Therapeutics.
At BIO Tuesday, panelists discussed the lack of racial, ethnic and gender diversity in clinical trials and its potential implications.
A new independent study from Phyx Primary Care’s Innovation Lab points to measurable improvements in physician burnout, documentation efficiency, and key VBC metrics among primary care practices.
Can we think of a less innovative word these days than "innovative?" BIO doesn't seem to care, given its hackneyed new name change.